Child Kidney Dis.  2023 Dec;27(2):64-69. 10.3339/ckd.23.015.

Comprehensive review of membranoproliferative glomerulonephritis: spotlighting the latest advances in revised classification and treatment

• Kim JY

• KMID: 2549735
• DOI: http://doi.org/10.3339/ckd.23.015

Abstract

Membranoproliferative glomerulonephritis (MPGN) is a complex group of renal diseases characterized by a specific pattern of glomerular injury that includes thickening of the capillary wall and mesangial expansion, leading to a heterogeneous group of conditions. This review article offers a comprehensive overview of MPGN, its new classification, pathophysiology, diagnostic evaluation, and management options.

Keyword

C3 glomerulopathy; C4 glomerulopathy; Dense deposit disease; Immunoglobulin/immune complex-mediated GN; Membranoproliferative glomerulonephritis

Figure

• 

  Fig. 1. Pathophysiology of membranoproliferative lesions [2-4]. MPGN, membranoproliferative glomerulonephritis; Ig, immunoglobulin; C3, complement component 3; C4, complement component 4; IC, immune complex; GN, glomerulonephritis; DDD, dense deposit disease; TMA, thrombotic microangiopathy.

• 

  Fig. 2. Nephrotic syndrome with normal or near-normal renal function treatment suggestion [2]. PD, prednisolone; PU, proteinuria; CNI, calcineurin inhibitor.

• 

  Fig. 3. Abnormal kidney function (without crescentic involvement) and active urine sediment with or without nephrotic-range proteinuria treatment suggestion [2]. PD, prednisolone; PU, proteinuria; MMF, mycophenolate mofetil.

Reference

References

1. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: a new look at an old entity. N Engl J Med. 2012; 366:1119–31.

2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021; 100(4S):S1–276.

3. Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD atlas of renal pathology: membranoproliferative glomerulonephritis. Am J Kidney Dis. 2015; 66:e19–20.

4. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol. 2011; 31:341–8.

5. Xu L, Wei F, Feng J, Liu J, Liu J, Tang X, et al. Characteristics and outcomes of glomerulonephritis with membranoproliferative pattern in children. Transl Pediatr. 2021; 10:2985–96.

6. Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012; 82:454–64.

7. Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, et al. C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial. Am J Kidney Dis. 2019; 74:224–38.

8. Angioi A, Fervenza FC, Sethi S, Zhang Y, Smith RJ, Murray D, et al. Diagnosis of complement alternative pathway disorders. Kidney Int. 2016; 89:278–88.

9. Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019; 15:45–59.

10. Pickering MC, D’Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013; 84:1079–89.

11. Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2007; 44:193–9.

12. Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. 2018; 93:977–85.

13. Ravindran A, Fervenza FC, Smith RJ, De Vriese AS, Sethi S. C3 glomerulopathy: ten years’ experience at Mayo Clinic. Mayo Clin Proc. 2018; 93:991–1008.

14. Sethi S, Quint PS, O’Seaghdha CM, Fervenza FC, Bijol V, Dorman A, et al. C4 glomerulopathy: a disease entity associated with C4d deposition. Am J Kidney Dis. 2016; 67:949–53.

15. Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and pathophysiological insights into immunological mediated glomerular diseases in childhood. Front Pediatr. 2020; 8:205.

16. Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol. 2015; 11:14–22.

17. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone: a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992; 6:123–30.

18. Kirpalani A, Jawa N, Smoyer WE, Licht C; Midwest Pediatric Nephrology Consortium. Long-term outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in children. Kidney Int Rep. 2020; 5:2313–24.

19. Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant. 2012; 27:4288–94.

20. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017; 91:539–51.

21. Medjeral-Thomas NR, O’Shaughnessy MM, O’Regan JA, Traynor C, Flanagan M, Wong L, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014; 9:46–53.

22. Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015; 88:1153–60.

23. Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol. 2018; 13:406–13.

24. Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, et al. Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis. 2018; 72:84–92.

25. Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H, et al. Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol. 2018; 22:797–807.

26. Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, et al. Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases. Am J Nephrol. 2013; 37:74–83.